Warning
Teva Pharmaceuticals USA Recalls Metoprolol Succinate Extended-Release Tablets
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0357-2026Drug / Pharmaceutical
Teva Pharmaceuticals USA Recalls Metoprolol Succinate Extended-Release Tablets
Teva Pharmaceuticals USA, Inc · Class II — Moderate Risk
Product Description
Metoprolol Succinate Extended-Release Tablets, 200 mg, 100 tablets bottles, Rx Only, Teva Pharmaceuticals, Parsippany, NJ 07054, NDC: 45963-678-11
Reason for Recall
Failed Dissolution Specifications
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
Nationwide
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
A Class II FDA recall has been issued for a pharmaceutical product from Teva Pharmaceuticals USA, Inc, initiated on January 29, 2026. Failed Dissolution Specifications. This recall covers 19,056 bottles, distributed nationwide. While not the highest severity, consumers should exercise caution and stop using the product until the recall is resolved.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medical Product Contamination and Teva Pharmaceuticals USA recalls.